文献速递类风湿关节炎

类风湿关节炎患者接种带状疱疹活疫苗的安全性及带状疱疹发生率:ORAL Strategy 事后分析

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-01-01

该事后分析基于ORAL Strategy随机对照研究,评估接受托法替布±甲氨蝶呤或阿达木单抗+甲氨蝶呤治疗的类风湿关节炎患者中,接种带状疱疹活疫苗(LZV)的安全性和带状疱疹(HZ)发生率。结果显示LZV耐受良好,各治疗组及接种与未接种者间HZ发生率总体相似,但研究把握度不足以比较接种与未接种患者,且LZV仅在约50%个体中显示有效。

要点

  • LZV在托法替布±MTX或ADA+MTX治疗的RA患者中耐受良好
  • 各治疗组及接种与未接种者间HZ发生率总体相似
  • 研究把握度不足以比较接种与未接种患者,LZV仅在约50%个体中有效

核心结论

  • LZV耐受良好,各治疗组及接种与未接种患者间HZ发生率总体相似。
  • ORAL Strategy研究把握度不足以比较接种与未接种患者,因接种者不足全部患者的20%。
  • LZV仅在约50%个体中显示有效。

研究设计与样本

  • ORAL Strategy为1年、IIIb/IV期、随机、三模拟、活性对照对照研究。
  • MTX应答不足的RA患者按1:1:1随机接受托法替布5 mg每日两次、托法替布5 mg每日两次+MTX或ADA 40 mg每两周一次+MTX。
  • 年龄≥50岁的符合条件患者可在开始研究治疗前28天选择接种LZV。
  • 共1146例患者中216例(18.8%)接种LZV。

主要发现

  • 共18例患者(1.6%)发生HZ,其中接种者3例,未接种者15例。
  • 托法替布单药、托法替布+MTX和ADA+MTX的HZ发生率分别为1.1(95%CI 0.3-2.9)、2.3(95%CI 1.0-4.6)和1.7(95%CI 0.6-3.7)/100患者年。
  • 发生3例多皮节型、1例播散型和2例严重HZ事件。
  • 接种后42天内无接种患者出现带状疱疹样皮损,1例患者出现接种部位红斑。

关键数值与推荐

  • HZ发生率以每100患者年发生事件的患者数计算。
  • 机会性HZ感染(多皮节型/播散型)、严重HZ事件和LZV相关不良事件被监测。

临床怎么用

  • 对于年龄≥50岁、计划接受托法替布±MTX或ADA+MTX治疗的RA患者,可考虑在开始治疗前28天接种LZV。
  • 接种LZV后需监测机会性HZ感染、严重HZ事件及疫苗相关不良事件。

局限性

  • ORAL Strategy研究把握度不足以比较接种与未接种患者,因接种者不足全部患者的20%。
  • LZV仅在约50%个体中显示有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore herpes zoster (HZ) rates and live zoster vaccine (LZV) safety in a subset of patients with rheumatoid arthritis who received LZV before tofacitinib ± methotrexate (MTX), or adalimumab (ADA) plus MTX in the ORAL Strategy. METHODS: ORAL Strategy was a 1-year, phase IIIb/IV, randomized, triple-dummy, active-comparator-controlled study. MTX-inadequate responder patients received tofacitinib 5 mg twice daily (BID), tofacitinib 5 mg BID plus MTX, or ADA 40 mg every other week plus MTX (1:1:1 randomization). Eligible patients age ≥50 years could opt to receive LZV 28 days before initiating study treatment. HZ incidence rates (IRs; patients with events per 100 patient-years) were calculated. Opportunistic HZ infections (multidermatomal/disseminated), serious HZ events, and LZV-related adverse events were monitored. RESULTS: In ORAL Strategy, 216 of 1,146 patients (18.8%) received LZV. Overall, 18 patients (1.6%) developed HZ (vaccinated: n = 3; nonvaccinated: n = 15). HZ IRs were 1.1 (95% confidence interval [95% CI] 0.3-2.9), 2.3 (95% CI 1.0-4.6), and 1.7 (95% CI 0.6-3.7) for tofacitinib monotherapy, tofacitinib plus MTX, and ADA plus MTX, respectively, and were generally similar between vaccinated and nonvaccinated patients. Three multidermatomal, 1 disseminated, and 2 serious HZ events occurred. No vaccinated patients had zoster-like lesions within 42 days of vaccination; 1 patient had vaccination-site erythema. CONCLUSION: LZV was well tolerated, and HZ IRs were generally similar between treatment groups and vaccinated versus nonvaccinated patients. However, ORAL Strategy was not powered for comparisons between vaccinated and nonvaccinated patients because <20% of all patients were vaccinated. Furthermore, LZV has been shown to be effective only in ~50% of individuals.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken). 2020. PMID: 31207152. doi:10.1002/acr.24010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。